Jacobs Levy Equity Management
OMGA

Jacobs Levy Equity Management’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Jacobs Levy Equity Management’s Portfolio OMGA Stock Details OMGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-279,464
Closed -$1.02M – 1067
2024
Q1 		$1.02M Sell
279,464
-18,817
-6% -$72.1K ﹤0.01% 713
2023
Q4 		$898K Buy
+298,281
New +$605K ﹤0.01% 741

Other funds holding OMGA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Jacobs Levy Equity Management's OMGA Position: Q2 2024 in Review

Jacobs Levy Equity Management sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q2 2024, closing a stake of 279,464 shares — an estimated $1.02M sold.

Jacobs Levy Equity Management first reported a position in OMGA in Q4 2023 and held it in 2 quarters. The position peaked at $1.02M in Q1 2024. 68 funds tracked by Wall St. Rank hold OMGA as of Q2 2024.

  • Jacobs Levy Equity Management reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 279,464 Omega Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $1.02M.
  • Jacobs Levy Equity Management first reported a position in Omega Therapeutics, Inc. Common Stock in Q4 2023 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Omega Therapeutics, Inc. Common Stock position peaked at $1.02M in Q1 2024.
  • 68 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2024, filed 14 Aug 2024.